How does solanezumab work?

Solanezumab is an antibody that aims to “clean” amyloid proteins from the blood and cerebrospinal fluid in an effort to prevent plaque formation.

How is solanezumab administered?

Treatment administration. In all EXPEDITION studies, patients were randomized to 400 mg solanezumab or placebo administered as an intravenous infusion of approximately 70 mL over at least 30 minutes Q4W for 18 months (approximately 80 weeks).

What is the CDR SB?

Background It was recently demonstrated that the Clinical Dementia Rating scale Sum of Boxes (CDR-SB) score can be used to accurately stage severity of Alzheimer dementia and mild cognitive impairment (MCI).

What is amyloid related imaging abnormalities?

Amyloid-related imaging abnormalities (ARIA) are abnormal differences seen in magnetic resonance imaging of the brain of Alzheimer’s disease patients, associated with amyloid-modifying therapies, particularly human monoclonal antibodies such as aducanumab.

What is the biological target and mechanism of action of solanezumab?

Solanezumab is a biological drug that targeted amyloid protein, a signature of Alzheimer’s disease, and was designed to break up the clumps of amyloid in the brain.

How is Gantenerumab administered?

Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. The treatment, administered as an injection under the skin, is now being developed with Hoffmann-La Roche in collaboration with MorphoSys.

Is Gantenerumab FDA approved?

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to gantenerumab, a human antibody that’s expected to slow or even prevent cognitive decline and memory loss in Alzheimer’s disease.

What is CDR GS?

Objective: The Clinical Dementia Rating (CDR) Scale comprising global score (CDR-GS) and sum of boxes scores (CDR-SB) is commonly used in staging cognitive impairment; however, its diagnostic accuracy is not well clarified.

How is CDR scored?

Clinical Dementia Rating (CDR) Ratings are assigned on a 0–5 point scale, (0 = absent; 0.5 = questionable; 1= present, but mild; 2 = moderate; 3 = severe; 4 = profound; 5 = terminal). A global summary score is obtained, leading to the use of the CDR for grouping patients on severity of dementia.

Is aducanumab available in UK?

Aducanumab remains unavailable in Europe and the UK.